CHLOR-DETOXNCT06026228
Effects of Probiotic Oral Intake on Plasma Chlordecone (Kepone) Concentrations in Individuals Environmentally Exposed to Pesticide in Martinique.
StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Feb 2024); last known: Not Yet Recruiting
- Notable Start date: Jan 2024 to Apr 2024
- Primary completion date: Jan 2026 to Apr 2026
- Study completion date: Aug 2026 to Oct 2026
- Notable Start date: Oct 2023 to Jan 2024
- Primary completion date: Oct 2025 to Jan 2026
- Study completion date: May 2026 to Aug 2026
- Minor Study description expanded, about 2 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Chlordeconemia
Timeframe: 6 months
Secondary (6)
Chlordeconemia
Variation of chlordeconemia
concentration of CLD in the stool
Variation of chlordecone concentration in stool
Plasma total cholesterol concentrations
Show 1 moreShow less
Clinical tolerance to BioGaia® Gastrus probiotic or placebo
Arms and interventions
Control groupPlacebo comparator
The control group will receive daily a placebo capsule per os at mealtime (just before or after) for a period of 6 months
Experimental groupExperimental
The experimental group will receive daily per os one capsule of BioGaia® Gastrus probiotic (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) dosed at 108 colony forming units (CFU)/day (distributed by the laboratory PEDIACT France), taken at mealtime (just before or after) for a period of 6 months
Dietary supplements: Limosilactobacillus reuteri
Other: Placebo
Sites
1 site in 1 country
- Centre Hospitalier Universitaire de Martinique - Hôpital Pierre ZOBDA QUITMANFort-de-France, France, Martinique